Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
News
Recent Posts
- Phase 2 trial planned to test oral therapy izicopan in AAV
- Redefining intimacy in life with chronic illness
- Advocates aim to foster connections this Vasculitis Awareness Month
- Kidney inflammation often worse for children with AAV vs. adults, study finds
- Using the spoon theory to manage my energy with chronic illness